MarketPulse
L

$LLY

175 articles found
110 positive
14 negative
50 neutral
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Pharma Giants Poised for Growth: Lilly, Vertex, Pfizer Lead March 2026 Rally

Eli Lilly dominates weight management, Vertex controls cystic fibrosis, and Pfizer offers undervalued shares with 6.3% dividend yield.
PFELLYVRTXdividend yieldcystic fibrosis
The Motley FoolThe Motley Fool··James Halley

Two Biotech Darlings Poised for Acquisition: Abivax and Nektar Signal M&A Targets

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.
AMGNABBVLLYAZNABVX+1acquisitionbiotech
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
BenzingaBenzinga··Vandana Singh

Eli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Faces Reality Check as Valuation Reaches Peak Levels

Eli Lilly's GLP-1 drugs drive 56% of revenues with explosive growth, but 43x P/E valuation leaves no room for disappointment amid intensifying competition and future patent risks.
PFELLYNVOGLP-1 drugsweight loss drugs
The Motley FoolThe Motley Fool··Will Healy

Major Shareholder Cashes Out $19.4M in Hut 8 Stake Amid Valuation Concerns

Ardsley Advisory Partners sells 440,000 Hut 8 shares (55% stake) worth $19.4M in Q4 2025, citing concerns over 26x price-to-sales valuation despite strong growth.
LLYAVGOHUTFSLRLITE+1cryptocurrencydata centers
GlobeNewswire Inc.GlobeNewswire Inc.··Amphista Therapeutics

Amphista Therapeutics Names New Leadership to Advance AMX-883 Toward IND Filing

Amphista Therapeutics appoints new CEO and CMO ahead of planned AMX-883 IND application in April 2026 for acute myeloid leukemia treatment.
LLYNVSclinical developmentIND application
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's Market Dominance vs. Viking's Promise: Weight Loss Drug Showdown

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.
LLYNVOVKTXclinical trialsmarket share
BenzingaBenzinga··Vandana Singh

HSBC Slashes Eli Lilly Price Target, Warns Obesity Drug Market Vastly Overhyped

HSBC downgraded $LLY to Reduce, citing inflated obesity market projections. The analyst sees $80-120B market by 2032, not Wall Street's $150B estimate.
LLYNVOprice target cutmarket valuation
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Novo Nordisk Faces Securities Fraud Investigation After CagriSema Trial Failure

Portnoy Law Firm investigates Novo Nordisk for possible securities fraud after CagriSema obesity drug failed trial, triggering 16.43% stock decline.
LLYNVOsecurities fraudclass action
Investing.comInvesting.com··Mike Zaccardi, Cfa, Cmt

Defensive Sectors Flash Mixed Signals as Volatility Spikes

Defensive sectors show conflicting technical signals: Utilities strengthen while Consumer Staples weaken and Health Care forms bearish patterns, creating mixed market outlook.
JNJWMTNVDALLYUNH+4market volatilitysector rotation
The Motley FoolThe Motley Fool··Adria Cimino

Pfizer at a Crossroads: Patent Cliffs and Pipeline Bets Define Next Chapter

Pfizer faces patent cliffs and COVID vaccine decline, betting on oncology and obesity drug pipelines to drive future growth amid acquisition integration challenges.
PFELLYNVOclinical trialsacquisitions
BenzingaBenzinga··Vandana Singh

Eli Lilly's Eczema Drug Clears Phase 3 Pediatric Hurdle, Eyes Label Expansion

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.
LLYFDA approvalPhase 3 trial
BenzingaBenzinga··Namrata Sen

Amgen, GSK Join TrumpRx Platform With Deep Discounts as Drug Pricing Pressure Mounts

Amgen and GSK join TrumpRx.gov offering up to 80% and 10-55% discounts respectively, expanding the platform to 54 drugs amid Trump administration pricing pressure.
AMGNPFELLYNVOAZN+1pharmaceutical companiesdrug affordability
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BIO-Europe Spring 2026 Poised for Record Dealmaking as 3,700+ Leaders Convene

BIO-Europe Spring 2026 in Lisbon expects 3,700+ attendees, 20,000+ meetings, and robust partnering activity as global biopharma industry seeks strategic deals and investment opportunities.
JNJLLYNVOGSKTEVAventure capitalLisbon
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Weight-Loss Dominance Faces Pipeline Challengers, But Lead Remains Secure

Eli Lilly dominates weight-loss pharmaceuticals with 45% 2025 revenue growth, maintaining market lead despite competitor advances due to years-long regulatory timelines.
LLYNVORHHBYREGNclinical trialsweight loss drugs
Investing.comInvesting.com··Jeffrey Neal Johnson

Eli Lilly's $3B China Bet: Securing GLP-1 Dominance in World's Largest Metabolic Market

Eli Lilly commits $3 billion to decade-long China expansion, targeting 141 million diabetics and 600 million overweight adults amid intense domestic competition.
LLYNVOsupply chainGLP-1 drugs
BenzingaBenzinga··Vandana Singh

Eli Lilly Warns of Unknown Impurity in Compounded Weight Loss Drugs

Eli Lilly warns of unidentified impurity in compounded tirzepatide weight loss drugs mixed with vitamin B12, urging FDA recalls and stricter oversight.
LLYweight loss drugsZepbound
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
BenzingaBenzinga··Vandana Singh

Eli Lilly Poised to Challenge AstraZeneca in Abivax Bidding War

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.
LLYAZNABVXacquisitionbiotech